Dermata Therapeutics Inc
$ 1.21
-5.47%
24 Feb - close price
- Market Cap 4,317,100 USD
- Current Price $ 1.21
- High / Low $ 1.25 / 1.16
- Stock P/E 0.09
- Book Value 4.69
- EPS 15.24
- Next Earning Report 2026-03-16
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.96 %
- ROE -2.03 %
- 52 Week High 14.60
- 52 Week Low 1.21
About
Dermata Therapeutics Inc. is a clinical-stage biotechnology firm dedicated to pioneering advanced therapies for various dermatological conditions. Its flagship product, DMT310, employs an innovative delivery method aimed at enhancing treatment efficacy for acne and other skin disorders. With a strategically developed pipeline and a focus on addressing significant unmet needs in dermatology, Dermata is well-positioned to lead in the skin health sector. As the company progresses through clinical trials, it seeks to harness its proprietary technology to provide patients with effective, safe, and user-friendly therapeutic solutions.
Analyst Target Price
$10.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-14 | 2025-08-13 | 2025-05-07 | 2025-03-17 | 2024-11-15 | 2024-08-15 | 2024-05-15 | 2024-03-21 | 2023-11-09 | 2023-08-10 | 2023-05-11 | 2023-02-21 |
| Reported EPS | -1.65 | -2.67 | -1.2515 | -0.92 | -20.4 | -4.18 | -7.05 | -0.21 | -0.54 | -0.63 | -2.27 | -2.4 |
| Estimated EPS | -0.32 | -0.44 | -0.45 | -0.32 | -26.4 | -3.79 | -5.4 | -0.78 | -0.63 | -0.92 | -2.65 | -3.2 |
| Surprise | -1.33 | -2.23 | -0.8015 | -0.6 | 6 | -0.39 | -1.65 | 0.57 | 0.09 | 0.29 | 0.38 | 0.8 |
| Surprise Percentage | -415.625% | -506.8182% | -178.1111% | -187.5% | 22.7273% | -10.2902% | -30.5556% | 73.0769% | 14.2857% | 31.5217% | 14.3396% | 25% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-16 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: DRMA
2026-02-14 00:57:51
This article provides an analysis of DERMATA THERAPEUTICS INC (DRMA) stock, including its current price, performance, and forecasts. It highlights the company's financial health, profitability, and analyst ratings, alongside a description of its clinical-stage medical dermatology focus and product candidates. Key statistics, technical and fundamental ratings, and competitor information are also presented.
2026-01-29 02:28:30
Dermata Therapeutics (DRMA) has expanded its at-the-market equity offering capacity with H.C. Wainwright & Co., LLC by an additional $705,000, following previous sales of $3.45 million in common shares. This move allows the company to raise further financing through share issuances, supporting funding needs while potentially diluting existing shareholders. TipRanks' AI Analyst, Spark, rates DRMA as Neutral, citing concerns about pre-revenue financial performance, persistent losses, cash burn, and dilution risk.
2026-01-28 02:57:44
Dermata Therapeutics (NASDAQ:DRMA) announced an increase of $705,000 to its at-the-market offering, expanding the total amount of common stock available for issuance. This move follows recent positive developments for the company, including a patent grant for its Spongilla technology in Australia and a $4.1 million private placement with insider participation. The company's stock has shown significant volatility but is up 32.8% year-to-date, reflecting ongoing efforts to strengthen its financial position and intellectual property.
2026-01-27 15:28:32
Dermata Therapeutics (NASDAQ:DRMA) announced an increase of $705,000 to its at-the-market offering agreement with H.C. Wainwright & Co., LLC, expanding the total amount of common stock available for issuance. The company's stock has seen significant volatility, with a 73.9% decline over the past year but a 32.8% gain year-to-date. This comes after recent news of a patent grant for its Spongilla technology for acne treatment in Australia and a $4.1 million private placement with insider participation.
2026-01-21 09:28:01
Dermata Therapeutics (NASDAQ:DRMA) has secured an Australian patent for its Spongilla technology to treat acne, enhancing its global intellectual property portfolio. The company plans to launch a related over-the-counter acne treatment in the U.S. in mid-2026 and is eyeing Australia as a future market. This follows a successful private placement that raised $4.1 million, with potential for an additional $8.3 million if warrants are fully exercised, bolstering the company's financial position for its strategic pivot into skincare solutions.
2026-01-21 04:57:46
Dermata Therapeutics, Inc. announced that the Australian Patent Office has granted a patent for its Spongilla technology combination as a method to treat acne, strengthening its global intellectual property. This follows a similar patent issued in the U.S. and positions Dermata to launch a new once-weekly, over-the-counter acne treatment system in mid-2026, initially in the U.S. The company views Australia as a key future market for this innovative treatment.
